Serum sodium trajectory during AKI and mortality risk

J Nephrol. 2022 Mar;35(2):697-701. doi: 10.1007/s40620-021-01225-5. Epub 2022 Jan 21.

Jonathan S Chávez-Íñiguez^{1

2}, Pablo Maggiani-Aguilera^{3

4}, Helbert Rondon-Berrios⁵, Kianoush B Kashani^{6

7}, Christian Pérez-Flores^{3

4}, Jorge Michel-González^{3

4}, Andres E De la Torre-Quiroga^{3

4}, Andrea Luna-Ramos^{3

4}, Guillermo Navarro-Blackaller^{3

4}, Alexia Romero-Muñoz^{3

4}, Ana T Martínez-Navarro^{3

4}, Gael Chávez-Alonso⁴, Ramón Medina-González³, Guillermo García-García^{3

4}

¹ Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde, Hospital 278, Colonia Centro, 44150, Guadalajara, Jalisco, Mexico. [email protected].
² University of Guadalajara Health Sciences Center, Guadalajara, Jalisco, Mexico. [email protected].
³ Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde, Hospital 278, Colonia Centro, 44150, Guadalajara, Jalisco, Mexico.
⁴ University of Guadalajara Health Sciences Center, Guadalajara, Jalisco, Mexico.
⁵ Renal-Electrolyte Division, University of Pittsburgh, Pittsburgh, USA.
⁶ Department of Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
⁷ Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

No abstract available

Keywords: Acute kidney injury; Kidney replacement therapy; Mortality; Serum sodium.

Publication types